{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are currently recognized as the most common genetic cause of parkinsonism. The G2019S variant is the most common LRRK2 mutation.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism relevant to the functional assay being described for the G2019S variant, linking it to parkinsonism."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Transgenic Drosophila over-expressing human LRRK2 G2019S exhibit late-onset loss of dopaminergic (DA) neurons in selected clusters that is accompanied by locomotion deficits.",
          "judgment": "Yes",
          "reasoning": "The general class of assay (transgenic Drosophila model) effectively models the disease pathogenesis/mechanism defined in Step 1.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Wild-type LRRK2 was used as a control, and the study mentions that three trials were performed in each experiment at 15 min intervals.",
          "judgment": "Yes",
          "reasoning": "Basic controls (wild-type LRRK2) and multiple replicates were used, meeting the criteria for this step.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study compares the effects of G2019S, Y1699C, and G2385R LRRK2 variants, which are known pathogenic variants, to wild-type LRRK2.",
          "judgment": "Yes",
          "reasoning": "Known pathogenic variants were used as controls, meeting the criteria for this step.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study does not provide statistical analyses sufficient to estimate or calculate OddsPath for the functional data.",
          "judgment": "Yes",
          "reasoning": "Since OddsPath calculation is not provided, we proceed to evaluate based on the number of variant controls used.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_moderate / Max BS3_moderate"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The G2019S variant in LRRK2 was assessed as having moderate pathogenic functional evidence (PS3_moderate) based on the transgenic Drosophila model showing late-onset loss of DA neurons and locomotion deficits, with appropriate controls and replicates."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "Y",
          "alt": "C",
          "position": "1699"
        },
        "variant_string_id": "LRRK2 Y1699C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The Y1699C variant is among the LRRK2 mutations identified to date, contributing to disease pathogenesis.",
          "judgment": "Yes",
          "reasoning": "The paper links the Y1699C variant to parkinsonism, defining the disease mechanism relevant to the functional assay."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Transgenic Drosophila over-expressing human LRRK2 Y1699C exhibit late-onset loss of DA neurons in selected clusters.",
          "judgment": "Yes",
          "reasoning": "The assay effectively models the disease pathogenesis/mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Wild-type LRRK2 was used as a control, and the study mentions that three trials were performed in each experiment at 15 min intervals.",
          "judgment": "Yes",
          "reasoning": "Basic controls and multiple replicates were used.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study compares the effects of Y1699C to other pathogenic variants and wild-type LRRK2.",
          "judgment": "Yes",
          "reasoning": "Known pathogenic variants were used as controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study does not provide statistical analyses sufficient to estimate or calculate OddsPath.",
          "judgment": "Yes",
          "reasoning": "OddsPath calculation is not provided, so evaluation is based on the number of variant controls used.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_moderate / Max BS3_moderate"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The Y1699C variant in LRRK2 was assessed as having moderate pathogenic functional evidence (PS3_moderate) based on the transgenic Drosophila model showing late-onset loss of DA neurons, with appropriate controls and replicates."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "R",
          "position": "2385"
        },
        "variant_string_id": "LRRK2 G2385R"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The G2385R variant is considered to be a risk allele among Asian population and contributes to disease pathogenesis.",
          "judgment": "Yes",
          "reasoning": "The paper links the G2385R variant to parkinsonism, defining the disease mechanism relevant to the functional assay."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Transgenic Drosophila over-expressing human LRRK2 G2385R exhibit late-onset loss of DA neurons in selected clusters.",
          "judgment": "Yes",
          "reasoning": "The assay effectively models the disease pathogenesis/mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Wild-type LRRK2 was used as a control, and the study mentions that three trials were performed in each experiment at 15 min intervals.",
          "judgment": "Yes",
          "reasoning": "Basic controls and multiple replicates were used.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study compares the effects of G2385R to other pathogenic variants and wild-type LRRK2.",
          "judgment": "Yes",
          "reasoning": "Known pathogenic variants were used as controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study does not provide statistical analyses sufficient to estimate or calculate OddsPath.",
          "judgment": "Yes",
          "reasoning": "OddsPath calculation is not provided, so evaluation is based on the number of variant controls used.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_moderate / Max BS3_moderate"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The G2385R variant in LRRK2 was assessed as having moderate pathogenic functional evidence (PS3_moderate) based on the transgenic Drosophila model showing late-onset loss of DA neurons, with appropriate controls and replicates."
    }
  ]
}